| Autor: |
Mussetti, Alberto, Bento, Leyre, Bastos-Oreiro, Mariana, Rius-Sansalvador, Blanca, Albo, Carmen, Bailen, Rebeca, Barba, Pere, Benzaquén, Ana, Briones, Javier, Caballero, Ana Carolina, Campos, António, Español, Ignacio, Ferra, Christelle, López, Sebastián Garzón, González Sierra, Pedro Antonio, Guerra, Luisa Maria, Hernani, Rafael, Iacoboni, Gloria, Jiménez-Ubieto, Ana, Kwon, Mi, Corral, Lucía López, López-Godino, Oriana, Munoz, Maria Carmen Martinez, Martínez-Cibrián, Nuria, Gómez, Juan Montoro, Pérez-Ortega, Laura, Ortí, Guillermo, Ortiz-Maldonado, Valentín, Pascual, Maria-Jesús, Perera, María, Perez, Antonio, Reguera, Juan Luis, Sanchez, Jose M., Sanz, Jaime, Torrent, Anna, Yáñez, Lucrecia, Varela, Rosario, Echechipia, Izaksun Ceberio, Caballero, Dolores, Sureda, Anna |
| Zdroj: |
Bone Marrow Transplantation; June 2023, Vol. 58 Issue: 6 p673-679, 7p |
| Abstrakt: |
Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the Grupo Español de Trasplante y Terapia Celular(GETH-TC) registry, we selected patients with the following characteristics: CART or alloHCT performed between 2016 and 2021; ≥18 years old; ABCL diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse. The analysis included a total of 316 (CART = 215, alloHCT = 101) patients. Median follow-up was 15 and 36 months for the CART and alloHCT cohorts, respectively. In the multivariate analysis, CART was confirmed to be similar to alloHCT for the primary study endpoint (progression-free survival) (hazard ratio [HR] 0.92, CI95%:0.56–1.51, p= 0.75). Furthermore, when the analysis was limited to only patients with chemo-sensitive diseases (complete and partial response) at infusion (CART = 26, alloHCT=93), no differences were reported (progression-free survival at month +18: 65% versus 55%, p= 0.59). However, CART had lower non-relapse mortality (HR 0.34, 95% CI: 0.13–0.85, p= 0.02). Given the lower toxicity and similar survival outcomes, these results suggest the use of CART before alloHCT. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink